Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy chain (Ig heavy chain)
- Target
- Ig heavy chain
- Molecular classification
- Antibody, Glycoprotein, Immunoglobulin superfamily (IgSF) protein
01
Overview
Immunoglobulin heavy chains are polypeptide components of antibody molecules. Each antibody (immunoglobulin) consists of two identical heavy chains and two identical light chains. Heavy chains define the antibody's isotype (e.g., IgG, IgM, IgA, IgE, IgD) and contain both variable regions, responsible for antigen binding, and constant regions, which determine effector functions such as complement activation and interaction with Fc receptors[1][2][4][5]. The term "beta chain" is not standard for immunoglobulins; “heavy chain” is the correct nomenclature, and these proteins form the backbone of antibody structure and function.
- Other names
- Ig heavy chainImmunoglobulin H chainH chain
02
Mechanism of action
Neutralization of antigens; Opsonization for phagocytosis; Antibody-dependent cell-mediated cytotoxicity (ADCC); Complement activation
03
Biological functions
Antigen bindingImmune responseOpsonizationComplement activationEffector cell activation (via Fc region)
04
Disease associations
Cancer (monoclonal gammopathies, multiple myeloma)Autoimmune diseases (autoantibody-related diseases)Infection (protective antibodies)
05
Safety considerations
Immunogenicity in therapeutic antibody useHypersensitivity reactions (e.g., serum sickness)Risk of immunosuppression when targeting B cells/antibodies
06
Interacting drugs
Rituximab (induces B cell depletion via antibodies)
2 more in the full profile.
07
Biomarkers
Monoclonal immunoglobulin (M-protein) in multiple myeloma, Waldenstrom macroglobulinemia, plasmacytomaFree light chain assays (for detection of abnormal immunoglobulin synthesis; context for "heavy" chain as well)
Beyond the preview
Go deeper on Immunoglobulin heavy chain (Ig heavy chain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy chain (Ig heavy chain).